September 30, 2020

Thinking About Medical Device Development Strategy in a Time of COVID-19

Pennovation Works


Ilisa Halpern Paul, president of the District Policy Group, and Partner Amy Judge-Prein and Associate Reed Abrahamson, discussed the importance of reimbursement strategy for emerging medical device companies, including measures companies can take ahead of FDA approval to promote a smooth coverage and reimbursement process and the ins and outs of Medicare reimbursement for medical device clinical trials. In addition, they provided best practices for planning and executing clinical trials during COVID-19.

Related Policy, Advocacy, and Consulting Services

Related Industries

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.